Claudia Duranti

Title: Claudia Duranti: Innovator in Antibody Research

Introduction

Claudia Duranti is a prominent inventor based in Pontassieve, Italy. She has made significant contributions to the field of medical sciences, particularly in the development of innovative antibody therapies. Her work focuses on the creation of bispecific antibodies that have the potential to revolutionize diagnostic and therapeutic approaches in oncology.

Latest Patents

Claudia holds a patent for her invention titled "Mono and bispecific antibody binding to hERG1 and hERG1/integrin beta 1." This invention describes a bispecific antibody composed of the variable domains (VH and VL) of two antibodies: hERG1 mAb, which binds the extracellular domain S5-P of hERG1, and β1 integrin mAb TS2/16 or BV7, which binds the extracellular domain of β1 integrin. Additionally, the invention relates to a novel anti-hERG1 molecule bearing a Cys in position 95 of the VH domain. The applications of this invention extend to diagnostic and therapeutic purposes in oncology and other fields of medical sciences. Claudia has 1 patent to her name.

Career Highlights

Claudia is affiliated with the University of Florence, where she conducts her research and contributes to the academic community. Her work has garnered attention for its innovative approach to addressing complex medical challenges.

Collaborations

Claudia collaborates with esteemed colleagues, including Annarosa Arcangeli and Laura Carraresi, who share her passion for advancing medical research and developing new therapeutic strategies.

Conclusion

Claudia Duranti's contributions to antibody research exemplify the innovative spirit of modern science. Her work not only enhances our understanding of antibody interactions but also paves the way for new treatments in oncology and beyond.